Cerulean Pharma Inc. CERU
No live quote for CERU yet.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 3.75
- Target (low)
- 1.50
- Target (mean)
- 3.75
- Target (high)
- 6.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 2
- 2 months ago 2
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.40 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.36 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 55.21M | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2016 | Wedbush | Downgrade | — | Neutral |
| Aug 17, 2016 | Leerink Swann | Downgrade | — | Market Perform |
| Aug 17, 2016 | Janney Capital | Downgrade | — | Neutral |
| Aug 17, 2016 | JMP Securities | Downgrade | — | Market Perform |
| Jan 5, 2016 | Janney Capital | Initiated | — | Buy |
| Sep 21, 2015 | Barclays | Initiated | — | Overweight |
| Aug 27, 2015 | Roth Capital | Initiated | — | Buy |
| May 5, 2014 | Leerink Swann | Initiated | — | Outperform |
| May 5, 2014 | Wedbush | Initiated | — | Outperform |
| May 5, 2014 | Canaccord Genuity | Initiated | — | Buy |
| May 5, 2014 | JMP Securities | Initiated | — | Market Outperform |